论文部分内容阅读
目的 检测葡萄膜黑色素瘤患者血清黑色素瘤活性抑制蛋白(MIA)的水平,并探讨其在葡萄膜黑色素瘤诊断和转移监测中的价值。 方法 应用酶联免疫吸附法(ELISA)分别检测不同组织病理分型的葡萄膜黑色素瘤(2 7例)、葡萄膜黑色素细胞瘤(6例)、其他眼部肿瘤患者(7例)以及正常成人(16人)外周血清中MIA的浓度。 结果 正常成人(16人)和睫状体无色素上皮腺瘤(4例)、视网膜母细胞瘤(2例)、视网膜血管瘤(1例)患者血清MIA浓度显著低于葡萄膜黑色素瘤患者;不伴巩膜浸润和远处转移的葡萄膜黑色素瘤患者血清MIA浓度明显低于伴有巩膜浸润和远处转移的患者,但与葡萄膜黑色素细胞瘤患者比较无明显差异;在不伴巩膜浸润和远处转移的葡萄膜黑色素瘤组,梭形细胞型患者血清MIA浓度与混合型和上皮细胞型患者相比无明显差异。 结论 血清MIA水平可能是临床诊断葡萄膜黑素瘤的一个较好指标,并且可用于肿瘤转移的监测。
Objective To investigate the serum level of melanoma inhibitory protein (MIA) in patients with uveal melanoma and to explore its value in the diagnosis and metastasis of uveal melanoma. Methods Cervical melanoma (27 cases), uveal melanocytoma (6 cases), other ocular tumors (7 cases) and normal adults were detected by enzyme linked immunosorbent assay (ELISA) (16) peripheral blood serum MIA concentration. Results Serum MIA levels were significantly lower in patients with uveal melanoma than in normal adults (16 patients), ciliary body ameloblastoma (4 patients), retinoblastoma (2 patients) and retinal hemangioma (1 patient) Serum MIA concentration in patients with uveal melanoma without scleral infiltration and distant metastasis was significantly lower than those with scleral infiltration and distant metastasis, but no significant difference with uveal melanocytoma patients; without scleral infiltration and There was no significant difference in serum MIA concentration in patients with distant metastasis of uveal melanoma and spindle cell type as compared with those in mixed type and epithelial type. Conclusions Serum MIA levels may be a good indicator of clinical diagnosis of uveal melanoma and may be used for the monitoring of tumor metastasis.